-
Cigarette smoking is a well-known risk factor for type 2 diabetes, but new research from Johns Hopkins suggests that quitting the habit may actually raise diabetes risk in the short term.
Johns Hopkins Hospital (Diabetology) - Tue, 27 July 2010
http://www.hopkinshospital.org
-
It is a widespread opinion that the inhibition of the rennin-angiotensin system can prevent diabetic nephropathy and that, through similar mechanisms, it is also capable to prevent retinopathy. In order to verify these hypotheses, an international randomized trial has been performed, involving 285 type 1 diabetics, with normal blood pressure, normal levels of urinary albumin, with an average HbA1c of 8.5% and with a duration of diabetes of over 10 years.
MedNews (Diabetology) - Thu, 22 July 2010
http://mn.medsurfnews.com/
-
In this randomized trial, sensor-augmented pump therapy was compared with a regimen of multiple daily insulin injections in adults and children with inadequately controlled type 1 diabetes. Pump therapy was associated with a significant improvement in glycated hemoglobin levels, as compared with injection therapy.
New England Journal of Medicine (Diabetology) - Thu, 22 July 2010
http://www.nejm.org
-
Given the fact that recent trials have doubted on the usefulness of an intensive control of glucose metabolism in type 2 diabetics, a systematic review has been now performed focusing on cardiovascular results.
MedNews (Diabetology) - Wed, 14 July 2010
http://mn.medsurfnews.com/
-
People with diabetes who undergo cancer surgery are more likely to die in the month following their operations than those who have cancer but not diabetes, an analysis by Johns Hopkins researchers suggests.
Johns Hopkins Hospital (Diabetology) - Wed, 14 July 2010
http://www.hopkinshospital.org
-
In order to verify the usefulness of drugs stimulating erythropoiesis in diabetics with anemia for chronic renal failure, a trial sponsored by pharmaceutical industry has been performed, randomizing 4038 type 2 diabetics (average age 68, 58% females) to receive darbepoietin alpha or placebo. Subjects were all affected by chronic renal failure (glomerular filtrate 20-60 ml/min/ m2) with hemoglobin levels < 11 g/dl. The dose of darbepoietin alpha was calculated in order to obtain a hemoglobin level approximately of 13 g/dl.
MedNews (Diabetology) - Mon, 5 July 2010
http://mn.medsurfnews.com/
-
Today's Lancet is a special issue on diabetes, published to coincide with the 70th Scientific Sessions meeting of the American Diabetes Association (ADA) in Orlando, Florida on June 26–29. Four Articles add precision to cardiovascular risk in people with type 2 diabetes, or describe new strategies in pharmacological pathways, dosing, and delivery. More studies will be published online during the meeting to coincide with a Lancet/ADA symposium. They will consider the treatment of women with diabetes during pregnancy, therapeutic comparisons in type 2 diabetes, and further results from the ACCORD study. Two Seminars examine diabetes mechanisms and epidemiology. In their totality, these publications represent great progress in the understanding of diabetes and the ability to lower concentrations of blood glucose. But there is a glaring absence: no research on lifestyle interventions to prevent or reverse diabetes. In this respect, medicine might be winning the battle of glucose control, but is losing the war against diabetes.
The Lancet (Diabetology) - Wed, 30 June 2010
http://www.thelancet.com
-
In type 2 diabetics, it is possible to use various insulin regimes. In order to clear up whether an optimal choice exists, the “4-T” trial has been performed, randomizing 708 diabetics under metformin and sulfonylurea therapy (with HbA1c between 7 and 10) to receive one of the following three insulin schemes, beside their usual therapy: an only daily dose of detemir insulin (Levemir) two daily doses of biphasic aspart insulin (Novomix 30) three daily doses, at meals, of aspart insulin (Novorapid)
MedNews (Diabetology) - Wed, 30 June 2010
http://mn.medsurfnews.com/
-
More people with diabetes are now receiving all nine of the key tests for diabetes care recommended by NICE, but thousands are still missing out on the essential tests, according to latest figures from the National Diabetes Audit.
National Institute for Health and Clinical Excellence (Diabetology) - Tue, 22 June 2010
http://www.nice.org.uk
-
The prevalence of OSAS (obstructive sleep apnea syndrome) is increasing, probably with obesity increasing, with all its cardiovascular consequences. In a trial on over 250 obese subjects (average BMI 37 kg/m2) affected by OSAS (average apnea-hypopnea index: 23 events/hour) and type 2 diabetes have been studied as to weight loss: they have been randomized to an intensive program of weight loss or to three sessions of training about glycemic control.
MedNews (Diabetology) - Wed, 16 June 2010
http://mn.medsurfnews.com/